Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Clinical Laserthermia Systems

7,59 SEK

+2,85 %

Mindre end 1K følgere

CLS B

First North Stockholm

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+2,85 %
-12,96 %
-35,79 %
+161,27 %
+107,38 %
+79,01 %
-85,03 %
-97,20 %
-96,92 %

Clinical Laserthermia Systems operates in the medical technology sector. The company's vision is to develop and streamline the treatment of solid cancer tumors, where the company is a seller of sterile patient kits. The products are used in various cancer treatments such as in the treatment of malignant melanoma, as well as cancer of the lungs, liver and pancreas. The company was founded in 2006 and has its headquarters in Lund.

Læs mere
Markedsværdi
236,55 mio. SEK
Aktieomsætning
319,38 t SEK
Omsætning
18,78 mio.
EBIT %
-288,87 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
20.2
2026

Årsrapport '25

15.5
2026

Delårsrapport Q1'26

14.8
2026

Delårsrapport Q2'26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse3.12.2025, 07.30

CLS: Clinical Laserthermia Systems Submits CE-Marking Application for its ClearPoint Prism[®][ ]branded Neuro Laser Therapy System seeking European Regulatory Approval for use in Neurosurgery

Clinical Laserthermia Systems
Pressemeddelelse17.11.2025, 08.32

Redeye: CLS Q3 (Review) - Soft sales, but better quarters ahead

Clinical Laserthermia Systems
Selskabsmeddelelse14.11.2025, 07.30

CLS Publishes Interim Report January - September 2025

Clinical Laserthermia Systems

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse7.10.2025, 20.15

CLS-sponsored neuro LITT study in patients with malignant brain tumor shows positive results

Clinical Laserthermia Systems
Selskabsmeddelelse30.9.2025, 11.35

CLS: Clinical Laserthermia Systems AB Raises SEK 20.9 Million Through Full Subscription of Warrants of Series TO 8 B

Clinical Laserthermia Systems
Selskabsmeddelelse4.9.2025, 15.00

CLS: Clinical Laserthermia Systems Receives FDA Clearance for Expanded Labeling of the ClearPoint Prism[®] Neuro Laser Therapy System, doubling the addressable U.S market for Neuro LITT

Clinical Laserthermia Systems
Pressemeddelelse25.8.2025, 09.20

Redeye: CLS Q2 - Strong report that reinforces confidence in outlook

Clinical Laserthermia Systems
Selskabsmeddelelse22.8.2025, 06.30

CLS publishes half-year report January - June 2025

Clinical Laserthermia Systems
Selskabsmeddelelse27.6.2025, 14.35

CLS: Communique from the Annual General Meeting on Friday June 27th in Clinical Laserthermia Systems A

Clinical Laserthermia Systems
Selskabsmeddelelse6.6.2025, 19.00

CLS: Clinical Laserthermia Systems publishes annual report for 2024

Clinical Laserthermia Systems
Selskabsmeddelelse27.5.2025, 09.00

CLS: Notice of Annual General Meeting of Clinical Laserthermia Systems AB June 27, 2025

Clinical Laserthermia Systems
Pressemeddelelse19.5.2025, 11.19

Redeye: CLS Q1 - A solid quarter largely in line with our expectations

Clinical Laserthermia Systems
Selskabsmeddelelse16.5.2025, 06.30

CLS: Clinical Laserthermia Systems AB publishes Interim report for January - March 2025

Clinical Laserthermia Systems
Selskabsmeddelelse28.4.2025, 06.30

CLS: Clinical Laserthermia Systems, together with its partner ClearPoint Neuro, announces FDA submission to expand the labeling of ClearPoint Prism® to include 1.5 T MRI guidance

Clinical Laserthermia Systems
Selskabsmeddelelse15.4.2025, 06.30

CLS: Updated clinical guidelines provide clear recommendations on the use of Laser Interstitial Thermal Therapy (LITT) in patients with metastatic brain tumors and radiation necrosis

Clinical Laserthermia Systems
Pressemeddelelse9.4.2025, 14.56

BioStock: CLS not significantly affected by tariffs

Clinical Laserthermia Systems
Selskabsmeddelelse8.4.2025, 11.45

Proposed U.S. tariffs expected to have minimal impact on CLS business

Clinical Laserthermia Systems
Pressemeddelelse27.2.2025, 11.16

BioStock: CLS raises up to 37 MSEK through directed share issue

Clinical Laserthermia Systems
Selskabsmeddelelse27.2.2025, 07.55

CLS: Clinical Laserthermia Systems AB raises up to SEK 37m through a directed issue for accelerated commercialization and expansion

Clinical Laserthermia Systems
Pressemeddelelse25.2.2025, 11.14

BioStock: CLS continues toward the goal of becoming cash flow positive by 2026

Clinical Laserthermia Systems
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.